Menu
Your Cart

HER3 ELISA Kit

HER3 ELISA Kit
HER3 ELISA Kit
  • Stock: In Stock
$680.00

Available Options

Description

HER3 ELISA Kit 

Catalog Number: HER3-01-1220

Size: 1 plate (96 wells)

HER3 ELISA Kit is a sandwich enzyme-linked immunoassay for the quantitative determination of HER3 with high sensitivity and specificity in serum or plasma.

   

Kit Performance

  • Sensitivity: 50 pg/mL
  • Assay Range: 50 – 1000 pg/mL
  • Cross-reactivity: There is no cross reaction with native immunoglobulins
  • Recovery rate: 80 – 120% with normal human serum or plasma samples with known concentrations.
  • Precision

(CV (%) = SD/mean X 100)

  • Intra-Assay: CV < 20%
  • Inter-Assay: CV < 20%

Materials Supplied

List of component

Components

  Quantity

High binding Plate

  1 plate

HER3

  1 µg

10x Capture

  700 µL

10x Detection

  700 µL

1x Streptavidin (HRP) (Avoid light)

  12 mL

1x Plate Coating Buffer

  15 mL

1x Blocking Buffer

  15 mL

2x Assay Diluent

  30 mL

1x TMB Substrate (Avoid light)

  12 mL

1x Stop Solution

  12 mL

 

Storage Instruction

The components arrive with ice pack, and must immediately be stored at 2-8°C. The kit components are stable at the date specified in CoA.

 

Supplementary information

HER3 (Human Epidermal Growth Factor Receptor 3), also known as ERBB3, is a member of the ERBB receptor tyrosine kinase family. Unlike other ERBB family members, HER3 has very weak intrinsic kinase activity. As a result, it cannot efficiently phosphorylate itself and instead relies on forming heterodimers with other ERBB receptors, most commonly HER2.

The HER2–HER3 heterodimer is considered one of the most potent signaling complexes in the ERBB network. HER3 contains multiple docking sites for the PI3K signaling pathway, allowing strong activation of the PI3K–AKT pathway, which promotes cell survival and resistance to apoptosis.

In cancer, HER3 itself is rarely amplified, but it often acts as a critical signaling partner for HER2 or EGFR-driven tumors. Increased HER3 expression or activation has been observed in several cancers, including breast, lung, ovarian, and gastric cancers.